Prostate cancer is a type of cancer that starts in the prostate gland, which is a small walnut-shaped gland in men that produces seminal fluid. It is the second most common cancer in men worldwide and the fourth most common cancer overall. Prostate cancer is usually slow-growing and may not cause any symptoms at first, but as cancer grows or spreads, it can cause problems with urination, sexual function, and other issues. While the causes of prostate cancer are not fully understood, risk factors include age, family history, and certain genetic mutations.
Early detection through screening and treatment can improve the chances of successful outcomes for those diagnosed with prostate cancer. It is often treated with surgery, radiation therapy, or other therapies. One such therapy is called focal ablative irreversible electroporation (IRE), which treats only the area of the tumor to achieve oncological control while reducing treatment-related functional decline.
A randomized clinical trial was conducted to evaluate the effect of focal vs extended IRE on early oncological control for patients with localized low- and intermediate-risk prostate cancer. The study involved 106 patients who were randomly assigned to receive either focal or extended IRE ablation. Data was collected at baseline and at regular intervals after the procedure from June 2015 to January 2020, and data were analyzed from September 2021 to July 2022.
The main thing the researchers wanted to know was if the treatment was good at stopping the cancer from growing back. They checked for cancer again 6 months after the treatment, and they found that there wasn't much difference between the two groups in how well the treatment worked.
The study found that focal IRE ablation therapy may provide acceptable oncological outcomes while preserving quality of life among patients with localized low- or intermediate-risk prostate cancer. This means that focal and extended IRE ablation achieved similar oncological outcomes in men with localized low- or intermediate-risk prostate cancer.
The study is significant because it offers another treatment option for patients with localized low- or intermediate-risk prostate cancer. This is important because some patients with intermediate-risk prostate cancer are still candidates for active surveillance. Focal therapy may be a promising option for those patients with a high risk of cancer progression.
It is important to note that while the study found that focal IRE ablation therapy may provide acceptable oncological outcomes, further studies are needed to confirm these findings. It is also important for patients to discuss all treatment options with their healthcare providers to determine the best course of action for their situation.
This clinical trial found that focal and extended IRE ablation achieved similar oncological outcomes. Focal IRE ablation therapy may provide acceptable oncological outcomes while preserving quality of life among patients with localized low- or intermediate-risk prostate cancer. Further studies are needed to confirm these findings, and patients should discuss all treatment options with their healthcare providers.